Amgen Korea and the Korea Health Industry Development Institute (KHIDI) said that they started accepting online applications for the 2025 KHIDI-Amgen Golden Ticket program, an open innovation initiative designed to support innovation in Korea’s pharmaceutical and biotechnology sectors.
Amgen Korea and KHIDI have opened applications for the 2025 Golden Ticket Program to support Korean biotech startups with global mentoring, consulting, and commercialization opportunities. (Credit: Amgen Korea)
Amgen Korea and KHIDI have opened applications for the 2025 Golden Ticket Program to support Korean biotech startups with global mentoring, consulting, and commercialization opportunities. (Credit: Amgen Korea)
Applications will be open from March 19 to April 16 through the program’s official website.
Korea is the fifth country to host the Golden Ticket program following the U.S., Canada, Singapore, and France. The first Korean edition of the program was successfully launched last year, receiving strong interest and support from Amgen’s global network.
This year’s program targets Korean companies researching three of Amgen’s key focus areas: next-generation therapeutics; novel targets and biology related to oncology, inflammation, cardiovascular diseases, and rare diseases; and artificial intelligence and data science-enabled drug discovery technologies.
Companies selected through document screening will be invited to present their technologies to Amgen’s global executives at the Golden Ticket Pitching Event, part of Bio Korea 2025.
The winning company will receive a one-year support package that includes global mentoring opportunities, expert consulting services from KHIDI, and access to office and networking space at the Golden Ticket Center.
“Amgen, as a global biotechnology leader, continues to support the international growth of innovative startups through open innovation,” Amgen Korea Head of Medical Kim Soo-a said. “Amgen Korea has served as a bridge between global and Korean biotech companies, and Korean participants have consistently demonstrated their capabilities, drawing increasing attention from our global teams.”
The company expects another promising company with advanced biotechnology to emerge from this year’s Golden Ticket program, he added.
KHIDI Biopharmaceutical Industry Team Lead Kim Yong-woo also said, “The Golden Ticket program shares Amgen’s global R&D expertise, while KHIDI offers a wide range of support for startup incubation and global expansion.”
KHIDI hopes participating companies will actively leverage this opportunity to become global leaders in biotech, Kim added.
tweet
Related articles
KHIDI seeks companies for 2025 Global Expansion Consulting Program
[Health Innovation③] Amgen Korea amplifies support for Korean biotech innovation through Golden Ticket program
Amgen Korea appoints Shin Su-hee as new GM
Lee Han-soo corea022@docdocdoc.co.kr
See Other Articles
Copyright © KBR Unauthorized reproduction, redistribution prohibited